Tag: Medicare Part D
The drug companies want $26,500 per year for the newest Alzheimer’s drug; negotiations might take it to $20,000. The potential for full Food and Drug Administration approval of the new Biogen-Esai Alzheimer’s drug (Leqembi) means that Medicare may make the drug available to beneficiaries. The $26,500 annual price tag associated with Leqembi will wreak havoc wit…
One last look at Aduhelm and Medicare. President Biden, in his State of the Union speech, proposed giving Medicare the ability to negotiate lower prices for prescription drugs. I’m assuming the President means not only over-the-counter drugs covered under Part D but also medications administered in a doctor’s office covered under Part B. Medicare sorely…
